Mutant PNPLA3 I148M Protein as Pharmacological Target for Liver Disease

Hepatology - United States
doi 10.1002/hep.29298
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

The PNPLA3 Variant Associated With Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation

Hepatology
MedicineHepatology
2017English

PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells

Hepatology Communications
Hepatology
2019English

The PNPLA3 I148M Variant Modulates the Fibrogenic Phenotype of Human Hepatic Stellate Cells

Hepatology
MedicineHepatology
2017English

The Rs738409 (I148M) Variant of the PNPLA3 Gene and Type 2 Diabetes in Yakutia

International Journal of Biomedicine
2018English

PNPLA3 Gene and Kidney Disease

2020English

Pharmacological Interventions for Non-Alcohol Related Fatty Liver Disease (NAFLD)

Cochrane Database of Systematic Reviews
2017English

Analysis of Polymorphic Options of the eNOS, PNPLA3, CD14 Genes at Alcoholic Liver Disease

Romanian Journal of Medical Practice
2019English

WIP1 Phosphatase as Pharmacological Target in Cancer Therapy

Journal of Molecular Medicine
Molecular MedicineDrug DiscoveryGenetics
2017English

Highlight Report: Caspase 8 as a Therapeutic Target in Chronic Liver Disease

Archives of Toxicology
MutagenesisToxicologyHealthMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy